{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:58:22Z","timestamp":1790398702079,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670495"],"award-info":[{"award-number":["81670495"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Crohn\u2019s disease (CD)-related fibrotic stricture remains a clinical challenge because of no effective treatments. This study aimed to evaluate the potential efficacy of rapamycin in patients with CD-related strictures in different locations in gastrointestinal tract. A pilot prospective study on using rapamycin for CD-related stricture was performed from April 2015 to August 2020 in a single center in China. Fifteen patients were enrolled into the study. The clinical efficacy was evaluated by diet score and gastrointestinal obstruction symptoms score. Clinical responses were defined as the ability to tolerate the regular diet with vegetable fiber combined with a reduction of \u226575% in overall target score and a score of less than two points for each item. Three patients discontinued rapamycin for less than 1-month due to intolerance to adverse events, then, 12 patients received \u22651 dose of the rapamycin and provided \u22651 post-baseline target score after baseline were included for intent-to-treat (ITT) analysis. 100% (5\/5) of patients with upper gastrointestinal strictures achieved clinical response after using rapamycin. However, no clinical response was observed in those patients with CD lesions in lower gastrointestinal tract. Adverse events occurred in 40% (6\/15) of patients. No death or serious opportunistic infections were observed in the present study. This study firstly reported that rapamycin might be effective for CD-related stricture in the upper, but not in lower gastrointestinal tract.<\/jats:p>","DOI":"10.3389\/fphar.2020.617535","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T02:15:23Z","timestamp":1612750523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Rapamycin is Effective for Upper but not for Lower Gastrointestinal Crohn\u2019s Disease-Related Stricture: A Pilot Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Min","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bota","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","article-title":"Cost-effectiveness of biological therapy for Crohn\u2019s disease: markov cohort analyses incorporating United Kingdom patient-level cost data","volume":"30","author":"Bodger","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e33626","DOI":"10.1371\/journal.pone.0033626","article-title":"Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/ecco-jcc\/jjaa008","article-title":"Transmural histology scores in stricturing crohn\u2019s disease: seeking to build precision on uncertain foundations","volume":"14","author":"Feakins","year":"2020","journal-title":"J. Crohns. Colitis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1097\/CM9.0000000000000954","article-title":"Nanjing consensus on methodology of washed microbiota transplantation","volume":"133","year":"2020","journal-title":"Chin. Med. J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/ecco-jcc\/jjv080","article-title":"Bowel damage as assessed by the Lemann Index is reversible on anti-TNF therapy for crohn\u2019s disease","volume":"9","author":"Fiorino","year":"2015","journal-title":"J. Crohns. Colitis."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004106","article-title":"Rifamycin attenuates cardiac fibrosis in experimental uremic cardiomyopathy by reducing marinobufagenin levels and inhibiting downstream pro-fibrotic signaling","volume":"5","author":"Haller","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1365-2036.2007.03532.x","article-title":"Systematic review: endoscopic dilatation in Crohn's disease","volume":"26","author":"Hassan","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/MCG.0000000000000041","article-title":"Exclusive enteral nutritional therapy can relieve inflammatory bowel stricture in Crohn\u2019s disease","volume":"48","author":"Hu","year":"2014","journal-title":"J. Clin. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/DCR.0b013e3182617716","article-title":"Risk factors for postoperative intra-abdominal septic complications after bowel resection in patients with Crohn\u2019s disease","volume":"55","author":"Kanazawa","year":"2012","journal-title":"Dis. Colon. Rectum."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1136\/gut.2008.157297","article-title":"Use of sirolimus (rapamycin) to treat refractory Crohn\u2019s disease","volume":"57","author":"Massey","year":"2008","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/s41385-019-0146-4","article-title":"Induction of autophagy in Cx3cr1(+) mononuclear cells limits IL-23\/IL-22 axis-mediated intestinal fibrosis","volume":"12","author":"Mathur","year":"2019","journal-title":"Mucosal Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.crohns.2014.08.014","article-title":"The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children","volume":"8","author":"Mutalib","year":"2014","journal-title":"J. Crohns. Colitis."},{"key":"B14","first-page":"249","article-title":"Duodenal Crohn\u2019s disease: an analysis of 89 cases","volume":"84","author":"Nugent","year":"1989","journal-title":"Am. J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/j.1572-0241.2008.02024.x","article-title":"A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn\u2019s disease","volume":"103","author":"Reinisch","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn\u2019s disease complicated by strictures: a systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2468-1253(19)30366-8","article-title":"Practical guidelines on endoscopic treatment for Crohn\u2019s disease strictures: a consensus statement from the global interventional inflammatory bowel disease group","volume":"5","author":"Shen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/ecco-jcc\/jjx078","article-title":"Efficacy, safety, and long-term outcome of serial endoscopic balloon dilation for upper gastrointestinal crohn's disease-associated strictures-A cohort study","volume":"11","author":"Singh","year":"2017","journal-title":"J. Crohns. Colitis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000486591","article-title":"Long-term outcome of endoscopic balloon dilatation for strictures in patients with crohn\u2019s disease","volume":"98","author":"Taida","year":"2018","journal-title":"Digestion"},{"key":"B20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00054725-200401000-00009","article-title":"Medical therapy for Crohn\u2019s disease strictures","volume":"10","author":"Van Assche","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bbrc.2017.06.074","article-title":"Rifamycin protects against paraquat-induced pulmonary fibrosis: activation of Nrf2 signaling pathway","volume":"490","author":"Xu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13238-019-00684-8","article-title":"Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening","volume":"11","author":"Zhang","year":"2020","journal-title":"Protein cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.617535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:42:01Z","timestamp":1612809721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.617535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":22,"alternative-id":["10.3389\/fphar.2020.617535"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.617535","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"article-number":"617535"}}